Legis Daily

BIOSECURE Act

USA118th CongressHR-8333| House 
| Updated: 9/10/2024
Brad R. Wenstrup

Brad R. Wenstrup

Republican Representative

Ohio

Cosponsors (14)
Elise M. Stefanik (Republican)Ashley Hinson (Republican)Neal P. Dunn (Republican)Darin LaHood (Republican)Stephanie I. Bice (Republican)Donald G. Davis (Democratic)Thomas R. Suozzi (Democratic)Raja Krishnamoorthi (Democratic)Anna G. Eshoo (Democratic)John R. Moolenaar (Republican)Mark E. Green (Republican)Seth Moulton (Democratic)Elissa Slotkin (Democratic)Josh Gottheimer (Democratic)

Homeland Security and Governmental Affairs Committee, Intelligence (Permanent Select) Committee, Oversight and Government Reform Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
BIOSECURE Act This bill prohibits entities that receive federal funds from using biotechnology that is from a company associated with a foreign adversary. Specifically, federal agencies and recipients of federal funds (e.g., grantees) may not procure or use any biotechnology equipment or service that is from a biotechnology company of concern and may not contract with any entities that do so. A biotechnology company of concern is an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). The Office of Management and Budget (OMB) must, in coordination with the Department of Defense (DOD) and other specified agencies, develop a list of prohibited companies; the list must include five particular companies, as specified in the bill. OMB and DOD may approve waivers of these restrictions on an as-needed basis, which are valid for up to one year and may be extended once for an additional 180 days. In addition, the Office of the Director of National Intelligence must report on the national security risks posed by (1) multiomic data collection by foreign adversaries in connection with biotechnology equipment or services, and (2) biotechnology companies that have such data.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 10, 2024
Introduced in House
May 10, 2024
Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 15, 2024
Committee Consideration and Mark-up Session Held
May 15, 2024
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.
Sep 9, 2024
Mr. Comer moved to suspend the rules and pass the bill, as amended.
Sep 9, 2024
Considered under suspension of the rules. (consideration: CR H5051-5058)
Sep 9, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 8333.
Sep 9, 2024
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Sep 9, 2024
Considered as unfinished business. (consideration: CR H5081-5082)
Sep 9, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402). (text: CR H5051-5052)
View Vote
Sep 9, 2024
Motion to reconsider laid on the table Agreed to without objection.
Sep 10, 2024
Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
  • May 10, 2024
    Introduced in House


  • May 10, 2024
    Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 15, 2024
    Committee Consideration and Mark-up Session Held


  • May 15, 2024
    Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.


  • September 9, 2024
    Mr. Comer moved to suspend the rules and pass the bill, as amended.


  • September 9, 2024
    Considered under suspension of the rules. (consideration: CR H5051-5058)


  • September 9, 2024
    DEBATE - The House proceeded with forty minutes of debate on H.R. 8333.


  • September 9, 2024
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • September 9, 2024
    Considered as unfinished business. (consideration: CR H5081-5082)


  • September 9, 2024
    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402). (text: CR H5051-5052)
    View Vote


  • September 9, 2024
    Motion to reconsider laid on the table Agreed to without objection.


  • September 10, 2024
    Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Health

Related Bills

  • S 118-3558: Prohibiting Foreign Access to American Genetic Information Act of 2024
AsiaChinaCongressional oversightDiplomacy, foreign officials, Americans abroadForeign and international corporationsGovernment employee pay, benefits, personnel managementGovernment information and archivesGovernment lending and loan guaranteesGovernment studies and investigationsHealth technology, devices, suppliesPublic contracts and procurement

BIOSECURE Act

USA118th CongressHR-8333| House 
| Updated: 9/10/2024
BIOSECURE Act This bill prohibits entities that receive federal funds from using biotechnology that is from a company associated with a foreign adversary. Specifically, federal agencies and recipients of federal funds (e.g., grantees) may not procure or use any biotechnology equipment or service that is from a biotechnology company of concern and may not contract with any entities that do so. A biotechnology company of concern is an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). The Office of Management and Budget (OMB) must, in coordination with the Department of Defense (DOD) and other specified agencies, develop a list of prohibited companies; the list must include five particular companies, as specified in the bill. OMB and DOD may approve waivers of these restrictions on an as-needed basis, which are valid for up to one year and may be extended once for an additional 180 days. In addition, the Office of the Director of National Intelligence must report on the national security risks posed by (1) multiomic data collection by foreign adversaries in connection with biotechnology equipment or services, and (2) biotechnology companies that have such data.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 10, 2024
Introduced in House
May 10, 2024
Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 15, 2024
Committee Consideration and Mark-up Session Held
May 15, 2024
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.
Sep 9, 2024
Mr. Comer moved to suspend the rules and pass the bill, as amended.
Sep 9, 2024
Considered under suspension of the rules. (consideration: CR H5051-5058)
Sep 9, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 8333.
Sep 9, 2024
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Sep 9, 2024
Considered as unfinished business. (consideration: CR H5081-5082)
Sep 9, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402). (text: CR H5051-5052)
View Vote
Sep 9, 2024
Motion to reconsider laid on the table Agreed to without objection.
Sep 10, 2024
Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
  • May 10, 2024
    Introduced in House


  • May 10, 2024
    Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 15, 2024
    Committee Consideration and Mark-up Session Held


  • May 15, 2024
    Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.


  • September 9, 2024
    Mr. Comer moved to suspend the rules and pass the bill, as amended.


  • September 9, 2024
    Considered under suspension of the rules. (consideration: CR H5051-5058)


  • September 9, 2024
    DEBATE - The House proceeded with forty minutes of debate on H.R. 8333.


  • September 9, 2024
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • September 9, 2024
    Considered as unfinished business. (consideration: CR H5081-5082)


  • September 9, 2024
    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402). (text: CR H5051-5052)
    View Vote


  • September 9, 2024
    Motion to reconsider laid on the table Agreed to without objection.


  • September 10, 2024
    Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Brad R. Wenstrup

Brad R. Wenstrup

Republican Representative

Ohio

Cosponsors (14)
Elise M. Stefanik (Republican)Ashley Hinson (Republican)Neal P. Dunn (Republican)Darin LaHood (Republican)Stephanie I. Bice (Republican)Donald G. Davis (Democratic)Thomas R. Suozzi (Democratic)Raja Krishnamoorthi (Democratic)Anna G. Eshoo (Democratic)John R. Moolenaar (Republican)Mark E. Green (Republican)Seth Moulton (Democratic)Elissa Slotkin (Democratic)Josh Gottheimer (Democratic)

Homeland Security and Governmental Affairs Committee, Intelligence (Permanent Select) Committee, Oversight and Government Reform Committee

Health

Related Bills

  • S 118-3558: Prohibiting Foreign Access to American Genetic Information Act of 2024
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
AsiaChinaCongressional oversightDiplomacy, foreign officials, Americans abroadForeign and international corporationsGovernment employee pay, benefits, personnel managementGovernment information and archivesGovernment lending and loan guaranteesGovernment studies and investigationsHealth technology, devices, suppliesPublic contracts and procurement